Advertisements
Feeds:
Posts
Comments

Search Results for 'PCSK9 '


 Cholesterol Lowering Novel PCSK9 drugs: Praluent [Sanofi and Regeneron] vs Repatha [Amgen] – which drug cuts CV risks enough to make it cost-effective? Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 1/15/2019 In the patent fight over PCSK9 inhibitors, the Supreme Court refused to hear Amgen’s appeal of a 2017 court decision allowing Sanofi and Regeneron […]

Read Full Post »


ODYSSEY Outcomes trial evaluating the effects of a PCSK9 inhibitor, alirocumab, on major cardiovascular events in patients with an acute coronary syndrome to be presented at the American College of Cardiology meeting on March 10. Reporter: Aviva Lev-Ari, PhD, RN   For PCSK9 inhibitors, the effect on major adverse cardiovascular events has always fallen short of expectations based on […]

Read Full Post »


FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN   Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »


Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic   Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 5/5/2017 Europeans Mull PCSK9i Post-FOURIER Fallout on Clinical Practice Patrice Wendling, May 04, 2017 But it was panelist Dr Stephen Nicholls (University of Adelaide, Australia) who […]

Read Full Post »


PCSK9 inhibitors: Reducing annual drug prices from more than $14 000 to $4536 would be necessary to meet a $100 000 per QALY threshold per JAMA Curator: Aviva Lev-Ari, PhD, RN   UPDATED on 6/21/2017 When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War – PCSK9 inhibitors https://www.wsj.com/articles/when-cholesterol-drugs-cost-14-000-an-insurance-tug-of-war-1497889667   Our team has researched PCSK9 inhibitors as a class of drugs […]

Read Full Post »


Efficacy and Tolerability of PCSK9 Inhibitors by Patients with Muscle-related Statin Intolerance – New Cleveland Clinic study published in JAMA 4/2016 Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN   Medical Interpretation of Study Results and the Pharmacological Treatment Context of PCSK9 Inhibitors Author: Larry H. Bernstein, MD, FCAP    The Rausse-3 Clinical […]

Read Full Post »


PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 3/28/2016 ·       by Crystal Phend  Senior Associate Editor, MedPage Today Alirocumab (Praluent) reduced the frequency of apheresis by 75% compared with placebo and eliminated the need for apheresis for 63%, according to top-line results from the 62-patient phase […]

Read Full Post »


FDA ask Regeneron and Sanofi to assess potential Neurocognitive Side Effects of Alirocumab, PCSK9 inhibitors Class Designed to Block a Protein causing Persistence of “bad” LDL Cholesterol in the Bloodstream Reporter & Curator: Aviva Lev-Ari, PhD, RN UPDATED on 3/23/2016 PCSK9 inhibitor, Praluent, shows promise in late-stage study in reducing the frequency of apheresis therapy, […]

Read Full Post »


SNPs in apoE are found to influence statin response significantly. Less frequent variants in PCSK9 and smaller effect sizes in SNPs in HMGCR Reporter: Aviva Lev-Ari, PhD, RN Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort John F. Thompson, PhD, Craig L. Hyde, PhD, Linda S. […]

Read Full Post »


Two Mutations, in the PCSK9 Gene: Eliminates a Protein involved in Controlling LDL Cholesterol Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 11/15/2013 Relax, PCSK9ers: FDA won’t roadblock blockbusters from Sanofi, Amgen By Damian Garde On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would […]

Read Full Post »

Next »